Dutch Institute for Rational Use of Medicines, Churchillaan 11, 3527 GV Utrecht, The Netherlands.
J Comp Eff Res. 2012 Nov;1(6):527-38. doi: 10.2217/cer.12.52.
Multiple reforms have recently been introduced in The Netherlands to improve prescribing efficiency. These include preference pricing policies for multiple sourced products, guidelines, and quality and efficiency targets, as well as regular pharmacotherapy meetings.
Assess the influence of these multiple measures on prescribing efficiency.
Retrospective observational study of all reimbursed prescriptions for proton pump inhibitors and statins between 2000 and 2010 using the Genees-en hulpmiddelen Informatie Project (Health Insurance) database. Utilization measured in defined daily doses. Narrative review of reforms.
Reimbursed expenditure for the proton pump inhibitors fell by 58% in 2010 versus 2000 despite a threefold increase in utilization, helped by increasing utilization of generic omeprazole at only 2% of the prepatent loss price in 2010. Similarly, reimbursed expenditure for the statins fell by 14% in 2010 versus 2000 despite a 3.8-fold increase in utilization. Again, this was helped by increasing utilization of generic simvastatin at only 2% of the prepatent loss originator price.
Multiple supply and demand measures, including the preference pricing policy, appear to have appreciably enhanced proton pump inhibitor and statin prescribing efficiency, providing examples to other countries.
近期荷兰实施了多项改革措施以提高处方效率。这些措施包括多来源产品的优惠定价政策、指南、质量和效率目标，以及定期的药物治疗会议。
评估这些多项措施对处方效率的影响。
使用 Genees-en hulpmiddelen Informatie Project（医疗保险）数据库，对 2000 年至 2010 年间质子泵抑制剂和他汀类药物的所有报销处方进行回顾性观察研究。利用定义日剂量来衡量利用率。对改革进行叙述性回顾。
尽管质子泵抑制剂的利用率增加了三倍，但 2010 年的报销支出与 2000 年相比下降了 58%，这得益于在 2010 年以仅为专利失效原始价格 2%的价格大量使用通用奥美拉唑。同样，他汀类药物的报销支出与 2000 年相比下降了 14%，尽管利用率增加了 3.8 倍。同样，这得益于以仅为专利失效原始价格 2%的价格大量使用通用辛伐他汀。
包括优惠定价政策在内的多项供应和需求措施似乎显著提高了质子泵抑制剂和他汀类药物的处方效率，为其他国家提供了范例。
